» Authors » Mara A Bonelli

Mara A Bonelli

Explore the profile of Mara A Bonelli including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 581
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Digiacomo G, Fumarola C, La Monica S, Bonelli M, Cretella D, Alfieri R, et al.
Front Oncol . 2020 Oct; 10:563249. PMID: 33072590
Advanced hepatocarcinoma (HCC) is an aggressive malignancy with poor prognosis and limited treatment options. Alterations of the cyclin D-CDK4/6-Rb pathway occur frequently in HCC, providing the rationale for its targeting...
2.
Fumarola C, Cretella D, La Monica S, Bonelli M, Alfieri R, Caffarra C, et al.
Oncotarget . 2017 Dec; 8(54):91841-91859. PMID: 29190880
Fibroblast Growth Factor Receptor (FGFR) signaling is a complex pathway which controls several processes, including cell proliferation, survival, migration, and metabolism. FGFR1 signaling is frequently deregulated via amplification/over-expression in NSCLC...
3.
Bonelli M, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, et al.
Neoplasia . 2017 Jul; 19(8):637-648. PMID: 28704762
Malignant pleural mesothelioma (MPM) is a progressive malignancy associated to the exposure of asbestos fibers. The most frequently inactivated tumor suppressor gene in MPM is CDKN2A/ARF, encoding for the cell...
4.
Bonelli M, Fumarola C, La Monica S, Alfieri R
Biochem Pharmacol . 2016 Jul; 123:8-18. PMID: 27431778
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesothelium, commonly associated to asbestos exposure. Therapeutic actions are limited due to the late stage at which...
5.
Bonelli M, Cavazzoni A, Saccani F, Alfieri R, Quaini F, La Monica S, et al.
Mol Cancer Ther . 2015 May; 14(8):1916-27. PMID: 26013318
A prominent role in the pathogenesis of squamous cell carcinoma of the lung (SQCLC) has been attributed to the aberrant activation of the PI3K signaling pathway, due to amplification or...
6.
Fumarola C, Bonelli M, Petronini P, Alfieri R
Biochem Pharmacol . 2014 May; 90(3):197-207. PMID: 24863259
While PI3K/AKT/mTOR pathway is altered in a variety of cancers including non small cell lung cancer, abnormalities in this pathway are more common in squamous cell lung carcinoma than in...
7.
Fumarola C, Caffarra C, La Monica S, Galetti M, Alfieri R, Cavazzoni A, et al.
Breast Cancer Res Treat . 2013 Aug; 141(1):67-78. PMID: 23963659
In this study, we investigated the effects and the underlying molecular mechanisms of the multi-kinase inhibitor sorafenib in a panel of breast cancer cell lines. Sorafenib inhibited cell proliferation and...
8.
Cavazzoni A, Bonelli M, Fumarola C, La Monica S, Airoud K, Bertoni R, et al.
Cancer Lett . 2012 Apr; 323(1):77-87. PMID: 22484466
Development of resistance to endocrine therapy is a clinical issue in estrogen receptor (ER)-positive breast cancer. Here we show that persistent activation of AKT/mTOR signaling is crucial to the acquisition...
9.
Bonelli M, Fumarola C, Alfieri R, La Monica S, Cavazzoni A, Galetti M, et al.
Breast Cancer Res Treat . 2010 Jan; 124(1):79-88. PMID: 20054642
Estrogens induce breast tumor cell proliferation by directly regulating gene expression via the estrogen receptor (ER) transcriptional activity and by affecting growth factor signaling pathways such as mitogen-activated protein kinase...
10.
Bonelli M, Desenzani S, Cavallini G, Donati A, Romani A, Bergamini E, et al.
Biogerontology . 2007 Sep; 9(1):1-10. PMID: 17902036
Proteasome activity is known to decrease with aging in ad libitum (AL) fed rats. Severe caloric restriction (CR) significantly extends the maximum life-span of rats, and counteracts the age-associated decrease...